Myb Sumoylation Site Antibody Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P10242 |
---|---|
Clone Names | 2110404 |
Gene ID | 4602 |
---|---|
Other Names | Transcriptional activator Myb, Proto-oncogene c-Myb, MYB |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2500a was selected from the region of a human Myb sumoylation site. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | MYB |
---|---|
Function | Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5'-YAAC[GT]G-3'. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells. |
Cellular Location | Nucleus {ECO:0000255|PROSITE-ProRule:PRU00625, ECO:0000269|PubMed:19646965} |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Myb is a transcriptional activator; DNA-binding protein that recognizes the sequence 5'-YAAC[GT]G-3'. It participates in the control of proliferation and differentiation of hematopoietic progenitor cells. Myb is a transcription factor related to Myc, and is expressed predominantly in haematopoietic cells and immature gastroepithelial cells. TRAF7 stimulates the sumoylation of Myb at Lys-523 and Lys-499, which are the same sites as those used for PIASy-induced sumoylation. A correlation has been established between reduction in sumoylation of Myb and increase in transcriptional activation. Negative influence on transactivation properties by the negative regulatory domain region of c-Myb depends on upon sumoylation.
References
Luchetti, M.M., et al., J. Biol. Chem. 278(3):1533-1541 (2003).Dahle, O., et al., Eur. J. Biochem. 270(6):1338-1348 (2003).Chen, J., et al., Oncogene 21(12):1859-1869 (2002).Hernandez-Munain, C., et al., J. Immunol. 169(8):4362-4369 (2002).Tanno, B., et al., J. Biol. Chem. 277(26):23172-23180 (2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.